



## Prion-like seeding and nucleation of intracellular amyloid- $\beta$

Tomas T. Olsson\*, Oxana Klementieva, Gunnar K. Gouras\*

Experimental Dementia Research Unit, Dept. of Experimental Medical Science, Lund University, Lund, Sweden



### ARTICLE INFO

#### Keywords:

Alzheimer's disease  
Amyloid  
Prion-like  
Oligomers  
FTIR

### ABSTRACT

Alzheimer's disease (AD) brain tissue can act as a seed to accelerate aggregation of amyloid- $\beta$  (A $\beta$ ) into plaques in AD transgenic mice. A $\beta$  seeds have been hypothesized to accelerate plaque formation in a prion-like manner of templated seeding and intercellular propagation. However, the structure(s) and location(s) of the A $\beta$  seeds remain unknown. Moreover, in contrast to tau and  $\alpha$ -synuclein, an *in vitro* system with prion-like A $\beta$  has not been reported. Here we treat human APP expressing N2a cells with AD transgenic mouse brain extracts to induce inclusions of A $\beta$  in a subset of cells. We isolate cells with induced A $\beta$  inclusions and using immunocytochemistry, western blot and infrared spectroscopy show that these cells produce oligomeric A $\beta$  over multiple replicative generations. Further, we demonstrate that cell lysates of clones with induced oligomeric A $\beta$  can induce aggregation in previously untreated N2a APP cells. These data strengthen the case that A $\beta$  acts as a prion-like protein, demonstrate that A $\beta$  seeds can be intracellular oligomers and for the first time provide a cellular model of nucleated seeding of A $\beta$ .

### 1. Introduction

Protein aggregation is a pathological hallmark of many neurodegenerative disorders such as amyloid- $\beta$  (A $\beta$ ) plaques and tau tangles in Alzheimer's disease (AD) and  $\alpha$ -synuclein containing Lewy bodies in Parkinson's disease (PD). However, how these proteins aggregate and spread throughout the brain remain poorly understood. A hypothesis that has been gaining traction the last decade is that these disease-linked proteins have prion-like properties. Prions are potentially infectious proteins that are capable of misfolding and aggregating (forming amyloid), inducing homologous proteins to misfold and, crucially, can spread and induce misfolding throughout the brain and even between organisms. There is evidence that  $\alpha$ -synuclein pathology might spread from host to graft in PD patients who received embryonic stem cell grafts (Kordower et al., 2008; Li et al., 2008) and between cells in culture (Hansen et al., 2011). Moreover, treatment with fibrillar  $\alpha$ -synuclein can seed intracellular inclusions in  $\alpha$ -synuclein expressing cells (Luk et al., 2009) and intracerebral injection of pathological  $\alpha$ -synuclein into  $\alpha$ -synuclein expressing mice accelerated formation of Lewy bodies and neurites (Luk et al., 2012). Tau has also been shown to spread between cells in culture (Holmes et al., 2013). Intracellular tau inclusions can be formed after addition of fibrillar tau to tau-fragment expressing HEK-293 cells, and injecting these cells into the brains of transgenic tau mice induced tau pathology (Sanders et al., 2014). For

A $\beta$ , studies have shown that intracerebral injections of AD brain material in familial AD (FAD) transgenic mice accelerate amyloid pathology and that it is specifically A $\beta$  that causes this as immunodepletion of A $\beta$  abolishes seeding activity (Kane et al., 2000; Meyer-Luehmann et al., 2006). Remarkably, as little as a femtogram of PBS soluble AD brain derived A $\beta$  can seed pathology in a FAD mouse (Fritsch et al., 2014). In contrast, much larger amounts of synthetic A $\beta$  either fail to seed plaques (Meyer-Luehmann et al., 2006) or require nitration or 72 h of agitation of the synthetic A $\beta$  to augment pathology (Kummer et al., 2011; Stöhr et al., 2012). It appears that only particular form(s) of A $\beta$  that is (are) present in AD but not normal brains are capable of seeding pathology, albeit in remarkably low quantities. On the basis of these findings it has been argued that A $\beta$  is a prion-like protein (Frost and Diamond, 2010; Jucker and Walker, 2011; Morales et al., 2015). Understanding where “prion-like” A $\beta$  can form and its structure would then be important for understanding the pathogenesis of AD.

While there is much *in vivo* work on prion-like A $\beta$ , it has not been shown that one can induce inclusions of A $\beta$  in cultured cells as has been shown for tau and  $\alpha$ -synuclein. One reason is practical; A $\beta$  is a low molecular weight metabolite cleaved from within the larger amyloid precursor protein (APP) and it is therefore less feasible to construct a cell line expressing physiologically generated, fluorescently labeled A $\beta$ . This makes it difficult to study A $\beta$  inclusions and transfer in cells. There

**Abbreviations:** FTIR, Fourier transform infrared spectroscopy; BN-PAGE, Blue native polyacrylamide gel electrophoresis; SDD-PAGE, Semi-denaturing detergent polyacrylamide gel electrophoresis

\* Corresponding authors.

E-mail addresses: [Tomas.Olsson@med.lu.se](mailto:Tomas.Olsson@med.lu.se) (T.T. Olsson), [Gunnar.Gouras@med.lu.se](mailto:Gunnar.Gouras@med.lu.se) (G.K. Gouras).

<https://doi.org/10.1016/j.nbd.2018.01.015>

Received 22 September 2017; Received in revised form 22 December 2017; Accepted 21 January 2018

0969-9961/© 2018 Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

is also a theoretical reason; as A $\beta$  plaques are extracellular, intracellular A $\beta$  has been viewed as less relevant. However, intraneuronal A $\beta$ 42 accumulation is seen before plaques in the brain areas first affected by AD and appears to be among the earliest changes in AD (Gouras et al., 2000) and is associated with synaptic pathology (Takahashi et al., 2002). Accumulation of intraneuronal A $\beta$  coincides with cognitive symptoms and occurs before plaques in the 3xTg AD mouse (Billings et al., 2005). Recently it was also reported that FAD mutations in presenilin 2 specifically increase the intracellular pool of A $\beta$ 42 (Sannerud et al., 2016). Furthermore, if conversion of monomeric to aggregated/prion-like A $\beta$  is a stochastic process (Goedert, 2015), one would expect the biological conversion to happen where concentrations are high as they are in subcellular compartments (Hu et al., 2009); the acidic environment of the late endosome/lysosome also favors A $\beta$  aggregation (Burdick et al., 1992). Thus, if A $\beta$  has prion-like properties, one might expect intracellular prion-like conversion as is the case for prion protein and other prion-like proteins (Aguzzi and Lakkaraju, 2016; Luk et al., 2009; Sanders et al., 2014).

In this study we induce human APP expressing N2a neuroblastoma cell lines to stably form intracellular inclusions of A $\beta$  by treating them with AD transgenic mouse brain extracts. We characterize these cell lines biochemically and with infrared (IR) absorbance spectroscopy and conclude that the inclusions are oligomers. We show that lysates of the inclusion bearing cells, a purely cellular source of A $\beta$ , can be used to induce naive APP-expressing cell lines to also form inclusions. In summary, we provide a cellular model of seeded nucleation of A $\beta$ , where the inclusion forming A $\beta$  can be propagated both vertically (the phenotype is stable over time) and horizontally (naive cells can be infected). These data are consistent with prion-like conversion of intracellular A $\beta$ .

## 2. Materials and methods

### 2.1. Preparation of mouse brain material

The forebrains of 21-month-old APP/PS1 (The Jackson laboratory, B6C3-Tg(APP<sup>swe</sup>,PSEN1<sup>dE9</sup>)85Dbo/Mmjax), Tg19959 harboring the Swedish and London mutations in APP (Li et al., 2004) or wild type (WT) mice were collected and immediately frozen on dry ice and stored at  $-80^{\circ}\text{C}$ . The forebrains were homogenized in 10% weight/volume sterile PBS, sonicated 3 times for 5 s at 80% amplitude with a Branson SLPe model 4C15 sonifier and centrifuged at 3000g for 5 min. The resulting supernatant was sonicated 3 times for 20 s each at 80% amplitude as described in Langer et al., 2011 (Langer et al., 2011). The supernatant was then aliquoted and kept at  $-80^{\circ}\text{C}$  until use.

### 2.2. Cell culture

N2a cells were grown in media containing 47% high glucose DMEM, 47% Optimem, 5% FBS and 1% penicillin/streptomycin at  $37^{\circ}\text{C}$  in a humid 5% CO<sub>2</sub> incubator. Single cell cloning was done *via* serial dilution in 96 well plates.

### 2.3. Cell pellet collection

Cells were washed twice on ice with ice-cold PBS and collected with a cell scraper. Cells were then pelleted at 10,600g for 2 min at  $4^{\circ}\text{C}$ , snap-frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ .

### 2.4. Treatment with brain supernatant

N2a cells expressing human APP with the Swedish mutation (APP<sup>swe</sup>) were passaged and the following day treated with brain supernatant at a concentration of 0.5% from either aged APP/PS1 or WT mice in Optimem with 1% penicillin/streptomycin and 0.5% FBS; low serum media was used to inhibit cell growth. The supernatant was kept

on the cells for 4 days at a time and then passaged and treated again or single cell cloned to isolate cells with aggregates.

### 2.5. Immunocytochemistry

Cells were grown on glass coverslips (VWR 12 mm microscope cover glasses). Cells were washed 3 times on ice with ice cold PBS, fixed with cold 4% PFA in PBS for 15 min at room temperature (RT) and then washed 3 times with PBS at RT. Blocking, to reduce unspecific antibody binding, was done with 2% NGS, 1% BSA and 0.1% saponin in PBS for 1 h. Cells were stained with primary A $\beta$ /C99 N-terminus-specific antibody 82E1 (IBL) at 1:200 and fibrillar oligomer-specific A $\beta$  antibody OC (Millipore) 1:1000 in PBS 2% NGS overnight at  $4^{\circ}\text{C}$ . Cells were then washed with PBS-T for 5 min, 15 min and 15 min. Then incubated with secondary antibodies at 1:500; AF488 anti-mouse and Cy3 anti-rabbit (Jackson ImmunoResearch) for 1 h at RT in the dark. Cells were again washed with PBS-T 3 times for 5 min each and during the second wash 0.1% DAPI was added. Coverslips were then mounted on glass slides with slow fade gold anti-fade reagent (Life Technologies) dried in the dark overnight and then sealed with Covergrip Coverslips Sealant (Biotum).

### 2.6. Confocal microscopy

Images were obtained using a Leica TCS SP8 confocal microscope (Leica Microsystems) equipped with Diode 405/405 nm and Argon (405, 488, 552, 638 nm) lasers with an HP PL APO 63x/NA1.2 water immersion objective. Autoquant (MediaCybernetics) was used for image deconvolution. Two-dimensional images obtained by confocal microscopy were reconstructed using Imaris (Bitplane).

### 2.7. Blue native (BN) PAGE

N2a cell pellets were triturated and incubated on ice for 30 min in a buffer solution of 20 mM Tris, 50 mM NaCl, 1% triton X pH adjusted to 7.4 with HCl and with 1:100 protease inhibitor cocktail (Thermo Fisher Scientific). The cells were then centrifuged at 10,600g at  $4^{\circ}\text{C}$  for 20 min, mixed with NativePAGE sample buffer 4 $\times$  (Thermo Fisher Scientific) and loaded onto 3–12 or 4–16% Bis Tris protein gels (Thermo Fisher Scientific). Native-Mark unstained protein standards (Invitrogen) were used as molecular weight markers with the addition of a 14 kDa marker (Sigma-Aldrich). Before protein transfer, the gels were washed with running buffer with 0.1% added SDS (Sigma) for 10 min. Transfers for all protein electrophoresis gels were done onto polyvinylidene difluoride (PVDF) membranes (iBlotR, NovexR, Life Technologies). Membranes were then boiled in PBS for 5 min and blocked in 5% skim milk in PBS-T for 30 min at RT. Primary antibody incubation was done at  $4^{\circ}\text{C}$  overnight in 5% skim milk PBS-T; for BN-PAGE, antibody 82E1 was used at 1:700. The membranes were then washed 4 times for 20 min each in PBS-T and incubated with secondary HRP antibody 1:2000 for 1 h in 5% skim milk in PBS-T at RT. The membranes were then washed 3 times for 15 min each in PBS-T and developed with Clarity western ECL blotting substrate (Bio-Rad).

### 2.8. Dot blot

Cell Samples were prepared as for BN-PAGE. 1  $\mu\text{l}$  of sample was put on a nitrocellulose membrane and allowed to dry and then washed with PBS-T for 15 min 3 times and blocked for 30 min in 5% skim milk PBS-T. Primary antibody incubation was done at  $4^{\circ}\text{C}$  overnight in 5% skim milk PBS-T and A11 or OC was used at a concentration of 1:5000. After primary incubation the procedure is identical to that of BN-PAGE.

### 2.9. Semi denaturing detergent (SDD) PAGE

The cells were either lysed as for BN PAGE or as 20% wt/vol

Download English Version:

<https://daneshyari.com/en/article/8686399>

Download Persian Version:

<https://daneshyari.com/article/8686399>

[Daneshyari.com](https://daneshyari.com)